Cancer treatment is now moving towards personalization, that is, the search for drugs that act on a patient’s unique tumor based on specific genetic and molecular characteristics. Most of these treatments are very effective, but not available for all cancers, including non-small cell lung cancer (NSCLC) with the LKB1 genetic mutation.
“Our results suggest that there is a way to target these cases with drugs that are FDA-approved or already in clinical trials, so this study could easily be used in human clinical trials,” the authors write.
After treating mice with LKB1-mutated lung cancer with various treatment regimens for 42 days, the team found that mice treated with entinostat and trametinib had 79% less tumor volume and 63% less tumors than mice that did not receive treatment.
News cannot be equated with a doctor’s prescription. Consult an expert before making a decision.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
